EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited

Walter Pirker, Regina Katzenschlager, Mark Hallett, Werner Poewe

Journal of Parkinson’s Disease · 02.03.2023 · 13 (2) · 127-144

DOI: 10.3233/jpd-225060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 21.02.2023. Verfasst von Walter Pirker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Klinik Ottakring, Vienna, Austria. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pathophysiology of Parkinson’s disease (PD) tremor remains incompletely understood and there is a lack of clinical trials specifically addressing its pharmacological treatment. Levodopa is the most efficacious drug for most patients and should be used as primary approach to control troublesome tremor. While the efficacy of oral dopamine agonists on PD tremor has been demonstrated in controlled trials, there is no evidence of greater antitremor efficacy compared to levodopa. The magnitude of the antitremor effect of anticholinergics is generally lower than that of levodopa. Due to their adverse effects, anticholinergics have a limited role in selected young and cognitively intact patients. Propranolol may improve resting and action tremor and may be considered as an adjunct in patients with insufficient tremor response to levodopa and this also applies to clozapine, despite its unfavorable adverse effect profile. Treating motor fluctuations with MAO-B and COMT inhibitors, dopamine agonists, amantadine, or on-demand treatments such as subcutaneous or sublingual apomorphine and inhaled levodopa as well as with continuous infusions of levodopa or apomorphine will improve off period tremor episodes. For patients with drug-refractory PD tremor despite levodopa optimization deep brain stimulation and focused ultrasound are first-line considerations. Surgery can also be highly effective for the treatment medication-refractory tremor in selected patients without motor fluctuations. The present review highlights the clinical essentials of parkinsonian tremor, critically examines available trial data on the effects of medication and surgical approaches and provides guidance for the choice of treatments to control PD tremor in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansLevodopaTremorDopamine AgonistsAntiparkinson AgentsApomorphineCholinergic Antagonists

Stichwörter der Autor:innen

Parkinson’s diseaselevodopalevodopa-resistancetreatmenttremor

Substanzen

LevodopaDopamine AgonistsAntiparkinson AgentsApomorphineCholinergic Antagonists

Autor:innen und Institutionen

  • Department of Neurology, Klinik Ottakring, Vienna, Austria.
  • Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Klinik Donaustadt, Vienna, Austria.
  • Human Motor Control Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Zitieren

APA

Pirker, W., Katzenschlager, R., Hallett, M., & Poewe, W. (2023). Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited. Journal of Parkinson’s Disease, 13(2), 127-144. https://doi.org/10.3233/jpd-225060

Vancouver

Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited. Journal of Parkinson’s Disease. 2023;13(2):127-144. doi:10.3233/jpd-225060

BibTeX
@article{Pirker2023,
  author = {Pirker, Walter and Katzenschlager, Regina and Hallett, Mark and Poewe, Werner},
  title = {Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited},
  journal = {Journal of Parkinson’s Disease},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {127--144},
  doi = {10.3233/jpd-225060}
}
Kostenlos starten →